• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lixte Biotechnology Holdings, Inc. - Common Stock (NQ:LIXT)

    7.210 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 7.210
    Bid (Size) 7.220 (200)
    Ask (Size) 7.590 (200)
    Prev. Close 7.210
    Today's Range 7.210 - 7.210
    52wk Range 2.360 - 8.377
    Shares Outstanding 5,704,200
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NetworkNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Completes NOMAD Merger, Changes Name to NOMAD Power Solutions
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Joins Russell Microcap(R) Index
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property

    Performance

    52-Week Range 13.9% below 52-week high
    7.210
    2.3652W Low 8.3852W High

    Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT) traded between $2.36 and $8.38 over the past 52 weeks and last traded at $7.21, 13.9% below its 52-week high.

    Past 12 Months
    N/A
    N/A
    N/A
    +150.3%
    +87.8%
    +35.5%
    1W  
    1M  
    3M  
    6M +$4.33
    YTD +$3.37
    1Y +$1.89

    LIXT was +35.5% over the past year, +150.3% over six months, +87.8% year to date.

    12 Months vs Market
    LIXT
    +35.5%
    DIA
    +9.3%
    SPY
    +15.0%
    QQQ
    +24.3%
    IWM
    +14.5%

    Over the past 12 months LIXT returned +35.5% versus DIA (Dow) +9.3%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +14.5%.

    Volume & Liquidity
    6M
    225.5K
    YTD
    145.3K
    1Y
    129.0K

    More News

    Read More
    News headline image
    A Nasdaq Company Just Reinvented Itself as a Power Company — and Bet It All on the AI Energy Crunch
    From World Street Intelligence
    Via GlobeNewswire
    MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances NOMAD Acquisition, Provides $6.5 Million Pre-Closing Loan
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    The AI Boom’s Real Bottleneck Is Power — and One Nasdaq Company Is Reinventing Itself to Solve It
    From USA News Group
    Via GlobeNewswire
    MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) to Acquire Mobile Energy Storage Provider NOMAD
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    The New Bottleneck Isn’t Computing Power — It’s Just Power
    From Equity Insider
    Via GlobeNewswire
    TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Prices $16.6 Million Registered Direct Offering
    Via Investor Brand Network
    Topics Intellectual Property
    BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Shifts Focus to AI Energy Infrastructure, Adds Denham Capital Founder to Board
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Reports First-Quarter Progress on Oncology Pipeline and Strategic Expansion
    Via Investor Brand Network
    Topics Intellectual Property
    TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment
    Via Investor Brand Network
    Topics Intellectual Property
    MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape
    Via Investor Brand Network
    Topics Intellectual Property
    Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built
    Via Investor Brand Network
    Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients
    Via Investor Brand Network
    BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference
    Via Investor Brand Network
    Topics Intellectual Property
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion
    Via Investor Brand Network
    Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
    Via Investor Brand Network
    MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year
    Via Investor Brand Network
    Topics Intellectual Property
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
    Via Investor Brand Network
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
    Via Investor Brand Network
    Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership
    Via Investor Brand Network
    Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming
    Via Investor Brand Network
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
    Via Investor Brand Network
    Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy
    Via Investor Brand Network
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships
    Via Investor Brand Network

    Frequently Asked Questions

    Is Lixte Biotechnology Holdings, Inc. - Common Stock publicly traded?
    Yes, Lixte Biotechnology Holdings, Inc. - Common Stock is publicly traded.
    What exchange does Lixte Biotechnology Holdings, Inc. - Common Stock trade on?
    Lixte Biotechnology Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock?
    The ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock is LIXT on the Nasdaq Stock Market
    What is the current price of Lixte Biotechnology Holdings, Inc. - Common Stock?
    The current price of Lixte Biotechnology Holdings, Inc. - Common Stock is 7.210
    When was Lixte Biotechnology Holdings, Inc. - Common Stock last traded?
    The last trade of Lixte Biotechnology Holdings, Inc. - Common Stock was at 07/02/26 04:00 PM ET
    What is the market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock?
    The market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock is 41.13M
    How many shares of Lixte Biotechnology Holdings, Inc. - Common Stock are outstanding?
    Lixte Biotechnology Holdings, Inc. - Common Stock has 41M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.